

# Synthesis and *in vitro* Biological Activity of New 4,6-Disubstituted 3(2*H*)-Pyridazinone-acetohydrazide Derivatives

Murat Sukuroglu<sup>a,\*</sup>, Tijen Onkol<sup>a</sup>, Fatma Kaynak Onurdağ<sup>b</sup>, Gulsen Akalın<sup>c</sup>, and M. Fethi Şahin<sup>a</sup>

<sup>a</sup> Gazi University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 06330 Ankara, Turkey. Fax: 90-312-2235018. E-mail: mkadir@gazi.edu.tr

<sup>b</sup> Gazi University, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, 06330 Ankara, Turkey

<sup>c</sup> Anadolu University, Faculty of Pharmacy, Department of Biochemistry, Eskisehir, Turkey

\* Author for correspondence and reprint requests

Z. Naturforsch. **67c**, 257–265 (2012); received July 6, 2011/February 7, 2012

New 3(2*H*)-pyridazinone derivatives containing a *N'*-benzyliden-acetohydrazide moiety at position 2 were synthesized. The structures of these newly synthesized compounds were confirmed by IR, <sup>1</sup>H NMR, and MS data. These compounds were tested for their antibacterial, antifungal, antimycobacterial, and cytotoxic activities. The compounds 2-[4-(4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-*tert*-butylbenzyliden)acetohydrazide and 2-[4-(4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-chlorobenzyliden)acetohydrazide exhibited activity against both Gram-positive and Gram-negative bacteria. Most of the compounds were active against *E. coli* ATCC 35218. The preliminary results of this study revealed that some target compounds exhibited promising antimicrobial activities.

**Key words:** Antimicrobial Activity, Benzyliden-acetohydrazide, Pyridazinone

## Introduction

For several years the emergence of multidrug-resistant bacteria and also -resistant fungi has been reported worldwide. Rapid development of multi-drug-resistant microbial pathogens such as methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *S. aureus* (VRSA), and vancomycin-resistant Enterococci (VRE) and the lack of effective treatments have made the treatment of infectious diseases as escalating problem (He *et al.*, 2003; Aksoy and Unal, 2008). Fungal infections are not limited to superficial tissues; in fact, advanced age, major surgery, immunosuppressive therapy, acquired immunodeficiency syndrome (AIDS), cancer treatment, and solid-organ and hematopoietic stem cell transplantation increase the risk of life-threatening systemic fungal infections (Sundriyal *et al.*, 2006). Therefore novel effective antimicrobial drugs are urgently required.

Pyridazinone derivatives have been reported to exhibit diverse pharmacological activities such as vasodilatory (Bansal *et al.*, 2009), antihypertensive (Demirayak *et al.*, 2004; Siddiqui *et al.*, 2010), antiplatelet (Cherng *et al.*, 2006), analgesic and anti-inflammatory (Gokce *et al.*, 2009), anticonvulsant (Rubat *et al.*, 1990), antibacterial (Longo *et al.*, 1993;

Sönmez *et al.*, 2006; Dogruer *et al.*, 2008), anti-HIV (Livermone *et al.*, 1993), and anticancer (Malinka *et al.*, 2004). Previously, we reported the analgesic and anti-inflammatory activity of novel series of 3(2*H*)-pyridazinones (Sukuroglu *et al.*, 2006; Dogruer *et al.*, 2003). Also, pyridazinones offer a valuable ring system to researchers because of easy functionalization at various ring positions. Also, *N*-acylhydrazone (NAH) compounds have been pointed out as promising antibacterial, antifungal (Suresh Kumar *et al.*, 2010; Mallikarjuna *et al.*, 2009), antimycobacterial (Sriram *et al.*, 2006), and antioxidant (Liu *et al.*, 2009) agents. Based on all above mentioned considerations and our interest in chemical and pharmacological properties of pyridazinones, we hereby report the synthesis and biological activities of novel 3(2*H*)-pyridazinones containing the *N'*-benzyliden-acetohydrazide moiety.

## Material and Methods

### Chemistry

Melting points were measured on an SMP-II digital melting point apparatus (Schorpp Gerätetechnik, Überlingen, Germany). Infrared (IR) spectra were recorded on a Perkin Elmer

Spectrum 400 FT-IR/FT-NR spectrophotometer (Waltham, MA, USA).

All chemicals used for the synthesis of the compounds were purchased from Aldrich Chemicals (Sigma-Aldrich, Steinheim, Germany) and Merck (Darmstadt, Germany). The  $^1\text{H}$  NMR spectra were recorded on a Varian Mercury 300 FT-NMR spectrometer (Varian Inc., Palo Alto, CA, USA). Chemical shifts ( $\delta$ ) are reported in parts per million (ppm) downfield from tetramethylsilane (TMS) as internal standard. DMSO- $d_6$  was used as solvent. High-resolution mass spectroscopy (HRMS) was done on a Micromass LCT Premier XE mass spectrometer (Waters, Milford, MA, USA) using an electrospray ion (ESI) source.

Synthesis of compounds **1** and **2** was accomplished according to the previously reported procedures (Sukuroglu *et al.*, 2006). Compounds **3a**, **3b**, and **4a–4r** were prepared for the first time in this study.

*Synthesis of 2-[4-(phenyl/4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-acetohydrazide (3a, 3b)*

Ethyl 2-[4-(phenyl/4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl] acetate (**2a**, **2b**) (0.01 mol) was refluxed with hydrazine hydrate (0.02 mol) in ethanol (20 mL) for 4 h. At the end of the period, the reaction mixture was cooled. The precipitate was filtered, dried, and crystallized from methanol.

*Synthesis of 2-[4-(phenyl/4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-benzyliden-acetohydrazide derivatives (4a–4r)*

2-[4-(Phenyl/4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]acetohydrazide (**3a**, **3b**) (0.01 mol), appropriate benzaldehyde derivatives (0.011 mol), and acetic acid (1–2 drops) were heated at reflux in ethanol for 3 h. The precipitated compound was filtered. The residue was washed with hot ethanol and dried.

2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]acetohydrazide (**3a**): IR:  $\nu$  = 1764 (C=O, CONH), 1671  $\text{cm}^{-1}$  (C=O, ring). –  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  = 3.23 (4H, t), 3.67 (4H, t), 4.23, 4.53 (2H, s), 7.49 (2H, d), 7.66 (1H, s), 7.86 (2H, d), 9.17 (1H, s). – HRMS (ESI $^+$ ): calcd. 364.1176 [M+H $^+$ ], found 364.1175.

2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]acetohydrazide (**3b**): IR:  $\nu$  = 1763 (C=O, CONH), 1671  $\text{cm}^{-1}$  (C=O, ring). –  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  = 3.20–3.21 (4H, m), 3.67 (4H, t), 4.20, 4.50 (2H, s), 7.38–7.39 (2H, m), 7.57 (1H, s), 7.75–7.77 (3H, m), 9.14 (1H, s). – HRMS (ESI $^+$ ): calcd. 330.1566 [M+H $^+$ ], found 330.1552.

2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-N'-benzyliden-acetohydrazide (**4a**): IR:  $\nu$  = 3203 (NH), 1687 (C=O, CONH), 1651  $\text{cm}^{-1}$  (C=O, ring). –  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  = 3.22–3.28 (4H, m), 3.68 (4H, t), 4.71, 5.11 (2H, s), 7.41 (4H, m), 7.50 (2H, d), 7.68–7.71 (3H, m), 7.89 (2H, d), 7.99, 8.19 (1H, s), 11.67 (1H, s). – HRMS (ESI $^+$ ): calcd. 452.1489 [M+H $^+$ ], found 452.1491.

2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-N'-(4-methylbenzyliden)acetohydrazide (**4b**): IR:  $\nu$  = 3182 (NH), 1679 (C=O, CONH), 1644  $\text{cm}^{-1}$  (C=O, ring). –  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  = 2.32 (3H, s), 3.20–3.29 (4H, m), 3.69 (4H, t), 4.70, 5.10 (2H, s), 7.24 (2H, d), 7.51 (2H, d), 7.58 (2H, d), 7.72 (1H, s), 7.89 (2H, d), 11.60 (1H, s). – HRMS (ESI $^+$ ): calcd. 466.1646 [M+H $^+$ ], found 466.1658.

2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-N'-(4-tert-butyl benzyliden)acetohydrazide (**4c**): IR:  $\nu$  = 3195 (NH), 1676 (C=O, CONH), 1649  $\text{cm}^{-1}$  (C=O, ring). –  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  = 1.26 (9H, s), 3.22–3.28 (4H, m), 3.68 (4H, t), 4.70, 5.09 (2H, s), 7.41 (2H, d), 7.50 (2H, d), 7.71 (1H, s), 7.89 (2H, d), 7.96, 8.15 (1H, s), 11.61 (1H, s). – HRMS (ESI $^+$ ): calcd. 508.2115 [M+H $^+$ ], found 508.2112.

2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-N'-(4-methoxybenzyliden)acetohydrazide (**4d**): IR:  $\nu$  = 3195 (NH), 1682 (C=O, CONH), 1643  $\text{cm}^{-1}$  (C=O, ring). –  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  = 3.21–3.28 (4H, m), 3.69 (4H, t), 3.78 (3H, s), 4.69, 5.09 (2H, s), 6.97 (2H, d), 7.51 (2H, d), 7.62 (2H, d), 7.71 (1H, s), 7.89 (2H, d), 7.93, 8.13 (1H, s), 11.53 (1H, s). – HRMS (ESI $^+$ ): calcd. 482.1595 [M+H $^+$ ], found 482.1615.

2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-N'-(4-ethoxybenzyliden)acetohydrazide (**4e**): IR:  $\nu$  = 3201 (NH), 1684 (C=O, CONH), 1643  $\text{cm}^{-1}$  (C=O, ring). –  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  = 1.31 (3H, t), 3.22–3.28 (4H, m), 3.68 (4H, t), 4.01–4.59 (2H, q), 4.68, 5.08 (2H, s),

6.94 (2H, d), 7.50 (2H, d), 7.60 (2H, d), 7.71 (1H, s), 7.89 (2H, d), 7.93, 8.12 (1H, s), 11.52 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 496.1752 [M+H<sup>+</sup>], found 496.1743.

2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-chlorobenzyliden)-acetohydrazide (**4f**): IR:  $\nu$  = 3203 (NH), 1687 (C=O, CONH), 1651 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>):  $\delta$  = 3.21–3.29 (4H, m), 3.69 (4H, t), 4.71, 5.12 (2H, s), 7.46–7.53 (4H, m), 7.72 (3H, m), 7.89 (2H, d), 7.99, 8.19 (1H, s), 11.72 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 486.1100 [M+H<sup>+</sup>], found 486.1086.

2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-fluorobenzyliden)-acetohydrazide (**4g**): IR:  $\nu$  = 3190 (NH), 1683 (C=O, CONH), 1644 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>):  $\delta$  = 3.24–3.29 (4H, m), 3.69 (4H, t), 4.71, 5.11 (2H, s), 7.23–7.28 (2H, m), 7.51 (2H, d), 7.72–7.85 (3H, m), 7.89 (2H, d), 7.99, 8.19 (1H, s), 11.68 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 470.1395 [M+H<sup>+</sup>], found 470.1395.

2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-trifluoromethylbenzyliden)acetohydrazide (**4h**): IR:  $\nu$  = 3198 (NH), 1684 (C=O, CONH), 1646 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>):  $\delta$  = 3.21–3.28 (4H, m), 3.68 (4H, t), 4.73, 5.14 (2H, s), 7.49–7.52 (2H, m), 7.72–7.90 (7H, m), 8.06, 8.26 (1H, s), 11.86 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 520.1363 [M+H<sup>+</sup>], found 520.1364.

2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(2-fluorobenzyliden)-acetohydrazide (**4i**): IR:  $\nu$  = 3193 (NH), 1685 (C=O, CONH), 1644 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>):  $\delta$  = 3.22–3.29 (4H, m), 3.69 (4H, t), 4.71, 5.12 (2H, s), 7.22–7.31 (2H, m), 7.46–7.52 (3H, m), 7.72 (1H, s), 7.88–7.95 (3H, m), 8.20, 8.42 (1H, s), 11.78 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 470.1395 [M+H<sup>+</sup>], found 470.1389.

2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-benzyliden-acetohydrazide (**4j**): IR:  $\nu$  = 3198 (NH), 1685 (C=O, CONH), 1649 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>):  $\delta$  = 3.67 (4H, t), 4.69, 5.10 (2H, s), 7.35–8.16 (11H, m), 11.69 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 418.1879 [M+H<sup>+</sup>], found 418.1876.

2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-methylbenzyliden)aceto-

hydrazide (**4k**): IR:  $\nu$  = 3201 (NH), 1684 (C=O, CONH), 1646 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DM-SO-*d*<sub>6</sub>):  $\delta$  = 2.28 (3H, s), 3.23 (4H, t), 3.66 (4H, t), 4.67, 5.07 (2H, s), 7.18–7.80 (10H, m), 7.93, 8.12 (1H, s), 11.57 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 432.2036 [M+H<sup>+</sup>], found 432.2036.

2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-*tert*-butylbenzyliden)aceto-hydrazide (**4l**): IR:  $\nu$  = 3195 (NH), 1685 (C=O, CONH), 1646 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DM-SO-*d*<sub>6</sub>):  $\delta$  = 1.24 (9H, s), 3.24–3.26 (4H, m), 3.66 (4H, t), 4.67, 5.07 (2H, s), 7.60–8.84 (10H, m), 7.93, 8.14 (1H, s), 11.57 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 474.2505 [M+H<sup>+</sup>], found 474.2508.

2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-methoxybenzyliden)aceto-hydrazide (**4m**): IR:  $\nu$  = 3201 (NH), 1680 (C=O, CONH), 1642 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DM-SO-*d*<sub>6</sub>):  $\delta$  = 3.24 (4H, t), 3.66 (4H, t), 3.75 (3H, s), 4.67, 5.07 (2H, s), 6.92–6.97 (2H, m), 7.40–7.41 (3H, m), 7.59–7.80 (5H, m), 8.03, 8.24 (1H, s), 11.82 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 448.1985 [M+H<sup>+</sup>], found 448.1978.

2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-ethoxybenzyliden)aceto-hydrazide (**4n**): IR:  $\nu$  = 3195 (NH), 1683 (C=O, CONH), 1644 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DM-SO-*d*<sub>6</sub>):  $\delta$  = 1.27 (3H, t), 3.26 (4H, t), 3.65 (4H, t), 3.97–4.03 (2H, q), 4.65, 5.05 (2H, s), 6.89–6.94 (2H, m), 7.39–7.79 (8H, m), 7.89, 8.09 (1H, s), 11.48 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 462.2141 [M+H<sup>+</sup>], found 462.2142.

2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-chlorobenzyliden)aceto-hydrazide (**4o**): IR:  $\nu$  = 3195 (NH), 1685 (C=O, CONH), 1648 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DM-SO-*d*<sub>6</sub>):  $\delta$  = 3.20–3.23 (4H, m), 3.66 (4H, t), 4.68, 5.09 (2H, s), 7.40–8.16 (11H, m), 11.69 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 452.1489 [M+H<sup>+</sup>], found 452.1483.

2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-fluorobenzyliden)aceto-hydrazide (**4p**): IR:  $\nu$  = 3206 (NH), 1685 (C=O, CONH), 1647 cm<sup>-1</sup> (C=O, ring). – <sup>1</sup>H NMR (DM-SO-*d*<sub>6</sub>):  $\delta$  = 3.20–3.23 (4H, m), 3.65 (4H, t), 4.67, 5.08 (2H, s), 7.18–7.78 (10H, m), 7.59, 8.16 (1H, s), 11.63 (1H, s). – HRMS (ESI<sup>+</sup>): calcd. 436.1785 [M+H<sup>+</sup>], found 436.1788.

2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(4-trifluoromethylbenzyliden)-acetohydrazide (**4q**): IR:  $\nu$  = 3208 (NH), 1687 (C=O, CONH), 1647  $\text{cm}^{-1}$  (C=O, ring). –  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  = 3.23–3.28 (4H, m), 3.65 (4H, t), 4.70, 5.11 (2H, s), 7.39–7.40 (3H, m), 7.63–7.89 (7H, m), 8.03, 8.24 (1H, s), 11.82 (1H, s). – HRMS (ESI $^+$ ): calcd. 486.1753 [M+H $^+$ ], found 486.1742.

2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-*N'*-(2-fluorobenzyliden)acetohydrazide (**4r**): IR:  $\nu$  = 3185 (NH), 1684 (C=O, CONH), 1646  $\text{cm}^{-1}$  (C=O, ring). –  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  = 3.22–3.26 (4H, m), 3.66 (4H, t), 4.68, 5.09 (2H, s), 7.19–7.41 (6H, m), 7.61–7.92 (4H, m), 8.18, 8.40 (1H, s), 11.74 (1H, s). – HRMS (ESI $^+$ ): calcd. 436.1785 [M+H $^+$ ], found 436.1785.

#### Antibacterial assay

The synthesized compounds were evaluated for their antibacterial activities against the Gram-negative bacteria *Escherichia coli* ATCC 35218, *E. coli* clinical isolate (ESBL), *Pseudomonas aeruginosa* ATCC 27853, *P. aeruginosa* clinical isolate, and the Gram-positive bacteria *Staphylococcus aureus* ATCC 29213, *S. aureus* clinical isolate (MRSA), *Enterococcus faecalis* ATCC 29212, *E. faecalis* clinical isolate. The tested isolates were provided by Gazi University, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Ankara, Turkey. Resistance in clinical isolates was determined by the disc diffusion method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI, 2006). All organisms were tested in triplicate in each run of the experiments.

All bacterial isolates were subcultured on Mueller-Hinton agar (MHA; Merck) and incubated overnight at 37 °C. The stock solutions of the newly synthesized compounds and standard drugs were diluted with liquid medium stepwise by half from 2048 down to 0.0625  $\mu\text{g/mL}$  in the wells of microplates. The bacterial susceptibility test was performed according to the guidelines of CLSI M100-S18 (CLSI, 2008a). The bacterial suspensions used for inoculation were prepared at  $10^5$  CFU/mL by diluting fresh cultures at a McFarland density of 0.5 ( $10^7$  CFU/mL), and the wells were inoculated at  $10^4$  CFU/mL. Mueller-Hinton broth (MHB; Merck) was used for all dilutions. Dimethyl sulfoxide (DMSO; Sigma Aldrich, Poole, UK), phosphate-buffered saline (PBS), pure microorganisms, and pure media

were used in control wells. A 10- $\mu\text{L}$  bacterial inoculum was added to each well. The trays were incubated at 37 °C, and minimum inhibitory concentration (MIC) endpoints were read after 24 h of incubation.

#### Antifungal assay

The newly synthesized compounds were evaluated for their antifungal activity against *Candida albicans* ATCC 10231 and *Candida krusei* ATCC 6258. All organisms were tested in triplicate in each run of the experiments.

*Candida* was subcultured on Sabouraud dextrose agar (SDA; Merck) and incubated at 35 °C for 24–48 h. Susceptibility testing was performed in RPMI-1640 medium supplemented with L-glutamine (Sigma) and buffered with 3-(*N*-morpholino)propanesulfonic acid (MOPS, pH 7; Sigma), and culture suspensions were prepared according to the guideline of CLSI M27-A3 (CLSI, 2008b). Yeast suspensions were prepared at a McFarland density of 0.5, and a working suspension was prepared by 1:100 dilution followed by 1:20 dilution of the stock suspension ( $2.5 \cdot 10^3$  CFU/mL). A 10- $\mu\text{L}$  yeast inoculum was added to each well of the microdilution trays. The trays were incubated at 35 °C, and MIC endpoints were read after 48 h of incubation.

#### Antimycobacterial assay

The *in vitro* activity of the synthesized compounds against *Mycobacterium tuberculosis* H37RV ATCC 27294 was determined by the microplate alamar blue assay (MABA) (Franzblau *et al.*, 1998). All organisms were tested in triplicate in each run of the experiments.

*Mycobacterium tuberculosis* H37RV ATCC 27294 was subcultured on Middlebrook 7H11 agar (Becton Dickinson, Franklin Lakes, NJ, USA). Culture suspensions were prepared in 0.04% (v/v) Tween 80/0.2% bovine serum albumin (Sigma) at a McFarland density of 1. Suspensions were then diluted 1:25 in 7H9GC broth (Difco, Le Pont de Claix, France), 20 mL of 10% (v/v) glycerol, 1 g of Bacto Casitone (Difco), 880 mL of distilled water, and 100 mL of Middlebrook OADC Growth Supplement (Sigma). The stock solutions of the newly synthesized compounds and standard drugs were diluted with liquid medium stepwise by half from 2048 down to 0.0625  $\mu\text{g/mL}$  in the wells of microplates in the liquid media. The plates were sealed with parafilm and incubated at 37 °C for 5 d. Fif-

ty  $\mu\text{L}$  of a freshly prepared 1:1 mixture of 10X alamar blue (AbD Serotec, Oxford, UK) reagent and 10% Tween 80 were added to the control well. The plates were incubated at 37 °C for 24 h. The control well turned pink, and the reagent mixture was added to all wells in the microplate. The microplates were resealed with parafilm and incubated for 24 h at 37 °C, and the colours of all wells were recorded. A blue colour in the well was scored as no growth and a pink colour as growth, respectively. The MIC was defined as the lowest drug concentration which prevented a colour change from blue to pink.

#### Cytotoxicity assay

The level of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) reduction was quantified as previously described in the literature with small modifications (Mossmann, 1983; Keiser *et al.*, 2000).

#### Cell culture and drug treatment

NIH/3T3 cells were obtained from the American Type Culture Collection (ATCC, CRL-1658). The cells were incubated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (Gibco, Paisley, Scotland), 100 IU/mL penicillin (Gibco), and 100 mg/mL streptomycin (Gibco) at 37 °C in a humidified atmosphere of 95% air and 5% CO<sub>2</sub>. Exponentially growing cells were plated at  $2 \cdot 10^4$  cells/mL into 96-well microtiter tissue culture plates (Nunc, Roskilde, Denmark) and incubated for 24 h and 48 h before the addition of the drugs (the optimum cell number for cytotoxicity assays was determined in preliminary experiments). Stock solutions of compounds were prepared in DMSO (Sigma Aldrich), and further dilutions were made with fresh culture medium (the content of DMSO in the final culture medium was <0.1% which had no effect on cell viability).

#### MTT assay for cytotoxicity tests of the compounds

After 24 h or 48 h of preincubation, the synthesized compounds were added to give final concentrations in the range 0.5–512  $\mu\text{M}$ , and the cells were incubated for 24 h. At the end of this period, MTT was added to a final concentration of 0.5 mg/mL, and the cells were incubated for 4 h at 37 °C. After the medium was removed, the formazan crystals formed were solubilized by addition of 200  $\mu\text{L}$  DMSO to each well, and absorbance was


read at 540 nm with a microtitre plate spectrophotometer (Bio-Tek plate reader; Winooski, VT, USA). Every concentration was repeated in three wells, and IC<sub>50</sub> values were defined as the drug concentrations that reduced absorbance to 50% of control values.

## Results and Discussion

We synthesized twenty new compounds, the synthetic route of which is outlined in Scheme 1. Procedures for the synthesis of compounds **1a**, **1b** and **2a**, **2b** have been reported by us in our previous study (Sukuroglu *et al.*, 2006). Compounds **3a**, **3b** and **4a–4r** were prepared for the first time in this study. 2-[4-(Phenyl/4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl]-acetohydrazide (**3a**, **3b**) was obtained by the reaction of ethyl 2-[4-(phenyl/4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2*H*)-pyridazin-2-yl] acetate with hydrazine hydrate in ethanol. The new compounds **4a–4r** were synthesized, in good yields, by condensing compounds **3a** and **3b** with the respective aromatic aldehydes in ethanol (Table I).

The structures of these stable and crystalline compounds were fully characterized by the usual methods (IR, <sup>1</sup>H NMR). In the IR spectra, N-H, C=O (acylhydrazone), and C=O (pyridazinone ring) peaks were seen at 3208–3183 cm<sup>-1</sup>, 1764–1676 cm<sup>-1</sup>, and 1671–1642 cm<sup>-1</sup>, respectively. In the <sup>1</sup>H NMR spectra of these compounds, signals due to N=CH and -CH<sub>2</sub>CO- groups appeared as two separate singlets. It is well known that *N*-acylhydrazones may exist as two geometrical isomers, *E/Z*. On the other hand, the reason for the existence of two different singlets of the -CH<sub>2</sub>CO- group may be due to two rotamers. This is, because the N-H group may form a hydrogen bond with the ring carbonyl group and thus form a pseudoring, which restricts the rotation. This suggestion may also be supported by the relative weakness of the ring carbonyl group peak in the IR spectra of the compounds (CLSI, 2006; CLSI, 2008b). High-resolution mass spectra confirmed the molecular masses and empirical formulas of compounds **3a**, **3b**, and **4a–4r**, with less than 5 ppm bias between calculated and experimental *m/z* values of the molecular ions.

The synthesized 3(2*H*)-pyridazinone derivatives **3a**, **3b**, and **4a–4r** were screened for their antibacterial, antifungal, and antimycobacterial activities. Twelve strains were used as test micro-



Scheme 1. Synthetic route towards 4,6-disubstituted 3(2*H*)-pyridazinone-acetohydrazide derivatives **4a–4r**. i, ethyl bromoacetate/ $K_2CO_3$ /DMF; ii,  $NH_2NH_2/C_2H_5OH$ ; iii, substituted benzaldehyde derivatives/HAc/ $C_2H_5OH$ .

organisms including ten bacterial and two fungal species, respectively. Ampicillin, gentamicin, amoxicillin, clavulanic acid, fluconazole, and amphotericin B for antibacterial activity, and ethambutol for antimycobacterial activity were used as

reference drugs. The minimal inhibitory concentration (MIC) values of the 3(2*H*)-pyridazinone derivatives are reported in Table II and Table III along with those of the standard drugs. The results revealed that the majority of the synthesized

Table I. Characteristics of compounds **3a**, **3b**, and **4a–4r**.

| Compound  | R <sup>1</sup> | Molecular formula                                                | M.p. [°C] | Yield (%) |
|-----------|----------------|------------------------------------------------------------------|-----------|-----------|
| <b>3a</b> | Cl             | C <sub>16</sub> H <sub>18</sub> N <sub>5</sub> O <sub>3</sub> Cl | 162       | 85        |
| <b>3b</b> | H              | C <sub>16</sub> H <sub>19</sub> N <sub>5</sub> O <sub>3</sub>    | 151–152   | 82        |
|           |                |                                                                  |           |           |

| Compound  | R <sup>1</sup> | R <sup>2</sup>                                                   | Molecular formula                                                              | M.p. [°C] | Yield (%) |
|-----------|----------------|------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------|-----------|
| <b>4a</b> | Cl             | C <sub>6</sub> H <sub>5</sub>                                    | C <sub>23</sub> H <sub>22</sub> N <sub>5</sub> O <sub>3</sub> Cl               | 242–243   | 73        |
| <b>4b</b> | Cl             | 4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                  | C <sub>24</sub> H <sub>24</sub> N <sub>5</sub> O <sub>3</sub> Cl               | 241–242   | 91        |
| <b>4c</b> | Cl             | 4-C(CH <sub>3</sub> ) <sub>3</sub> C <sub>6</sub> H <sub>4</sub> | C <sub>27</sub> H <sub>30</sub> N <sub>5</sub> O <sub>3</sub> Cl               | 260–261   | 86        |
| <b>4d</b> | Cl             | 4-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>                 | C <sub>24</sub> H <sub>24</sub> N <sub>5</sub> O <sub>4</sub> Cl               | 247–248   | 90        |
| <b>4e</b> | Cl             | 4-C <sub>2</sub> H <sub>5</sub> OC <sub>6</sub> H <sub>4</sub>   | C <sub>25</sub> H <sub>26</sub> N <sub>5</sub> O <sub>4</sub> Cl               | 258–259   | 88        |
| <b>4f</b> | Cl             | 4-ClC <sub>6</sub> H <sub>4</sub>                                | C <sub>23</sub> H <sub>21</sub> N <sub>5</sub> O <sub>3</sub> Cl <sub>2</sub>  | 240       | 64        |
| <b>4g</b> | Cl             | 4-FC <sub>6</sub> H <sub>4</sub>                                 | C <sub>23</sub> H <sub>21</sub> N <sub>5</sub> O <sub>3</sub> ClF              | 219       | 87        |
| <b>4h</b> | Cl             | 4-CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                  | C <sub>24</sub> H <sub>21</sub> N <sub>5</sub> O <sub>3</sub> ClF <sub>3</sub> | 253       | 84        |
| <b>4i</b> | Cl             | 2-FC <sub>6</sub> H <sub>4</sub>                                 | C <sub>23</sub> H <sub>21</sub> N <sub>5</sub> O <sub>3</sub> ClF              | 249–250   | 87        |
| <b>4j</b> | H              | C <sub>6</sub> H <sub>5</sub>                                    | C <sub>23</sub> H <sub>23</sub> N <sub>5</sub> O <sub>3</sub>                  | 212–213   | 82        |
| <b>4k</b> | H              | 4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                  | C <sub>24</sub> H <sub>25</sub> N <sub>5</sub> O <sub>3</sub>                  | 235–236   | 78        |
| <b>4l</b> | H              | 4-C(CH <sub>3</sub> ) <sub>3</sub> C <sub>6</sub> H <sub>4</sub> | C <sub>27</sub> H <sub>31</sub> N <sub>5</sub> O <sub>3</sub>                  | 255       | 89        |
| <b>4m</b> | H              | 4-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>                 | C <sub>24</sub> H <sub>25</sub> N <sub>5</sub> O <sub>4</sub>                  | 233       | 87        |
| <b>4n</b> | H              | 4-C <sub>2</sub> H <sub>5</sub> OC <sub>6</sub> H <sub>4</sub>   | C <sub>25</sub> H <sub>27</sub> N <sub>5</sub> O <sub>4</sub>                  | 251       | 87        |
| <b>4o</b> | H              | 4-ClC <sub>6</sub> H <sub>4</sub>                                | C <sub>23</sub> H <sub>22</sub> N <sub>5</sub> O <sub>3</sub> Cl               | 251–252   | 90        |
| <b>4p</b> | H              | 4-FC <sub>6</sub> H <sub>4</sub>                                 | C <sub>23</sub> H <sub>22</sub> N <sub>5</sub> O <sub>3</sub> F                | 229       | 88        |
| <b>4q</b> | H              | 4-CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                  | C <sub>24</sub> H <sub>22</sub> N <sub>5</sub> O <sub>3</sub> F <sub>3</sub>   | 239–240   | 81        |
| <b>4r</b> | H              | 2-FC <sub>6</sub> H <sub>4</sub>                                 | C <sub>23</sub> H <sub>22</sub> N <sub>5</sub> O <sub>3</sub> F                | 205       | 86        |

[illegible]

compounds showed varying degrees of inhibition against the selected test microorganisms.

Among the tested compounds, compound **4b** was most active (MIC 16  $\mu\text{g/mL}$ ), with a 50% higher rate than amoxicillin/clavulanic acid, against *E. coli* ATCC 35218. While the antibacterial activities of compounds **4c**, **4h**, and **4q** (MIC 32  $\mu\text{g/mL}$ ) were found to be 25% that of the reference drug, compounds **3a**, **3b**, **4e**, **4f**, **4i**, **4j**, **4k**, **4l**, **4m**, **4n**, **4p**, and **4r** exhibited antibacterial activity at 64  $\mu\text{g/mL}$  against *E. coli* ATCC 35218. Among the synthesized compounds **4e**, having an MIC value of 8  $\mu\text{g/mL}$ , was found to be the most active derivative against the Gram-positive bacterium *E. faecalis* ATCC 29212. Compounds **4c**, **4f**, and **4q** had lower MIC values (64  $\mu\text{g/mL}$ ) than compounds **4a**, **4b**, **4h**, **4i**, **4o**, and **4p** (128  $\mu\text{g/mL}$ ) against *E. faecalis* ATCC 29212. Furthermore, the compounds were inactive against *P. aeruginosa* ATCC 27853. The results given in Table II indicate that among the new compounds tested, only compound **4h** showed a somewhat higher antifungal activity against *C. albicans* ATCC 10231 than the others.

Table III. MIC values of 4,6-disubstituted 3(2*H*)-pyridazinone-acetohydrazide derivatives against *M. tuberculosis*.

| Compound   | Minimum inhibitory concentration<br>[ $\mu\text{g/mL}$ ] |                                   |
|------------|----------------------------------------------------------|-----------------------------------|
|            | <i>M. tuberculosis</i><br>H37RV ATCC<br>27294            | <i>M. tuberculosis</i><br>isolate |
| <b>3a</b>  | 256                                                      | 128                               |
| <b>3b</b>  | 256                                                      | 128                               |
| <b>4a</b>  | 512                                                      | 128                               |
| <b>4b</b>  | 512                                                      | 128                               |
| <b>4c</b>  | 512                                                      | 128                               |
| <b>4d</b>  | 512                                                      | 128                               |
| <b>4e</b>  | 512                                                      | 128                               |
| <b>4f</b>  | 256                                                      | 128                               |
| <b>4g</b>  | 512                                                      | 128                               |
| <b>4h</b>  | 512                                                      | 128                               |
| <b>4i</b>  | 512                                                      | 128                               |
| <b>4j</b>  | 512                                                      | 128                               |
| <b>4k</b>  | 256                                                      | 128                               |
| <b>4l</b>  | 256                                                      | 128                               |
| <b>4m</b>  | 256                                                      | 128                               |
| <b>4n</b>  | 256                                                      | 128                               |
| <b>4o</b>  | 256                                                      | 128                               |
| <b>4p</b>  | 256                                                      | 128                               |
| <b>4q</b>  | 256                                                      | 128                               |
| <b>4r</b>  | 256                                                      | 256                               |
| Ethambutol | 4                                                        | 1                                 |

In comparison to their antibacterial activity, none of the compounds had promising antifungal activity against *C. albicans* and *C. krusei*. The acylhydrazones **4a–4r** inhibited *M. tuberculosis* with MIC values ranging from 256 to 512  $\mu\text{g/mL}$ , and were less effective than the reference drug (Table III).

In general, the inhibitory activities of the compounds tested against the Gram-negative bacteria were higher than those against the Gram-positive bacteria. Compounds **4c**, **4f**, and **4q** exhibited both Gram-positive and Gram-negative antibacterial activity. Therefore, one can state that the presence of electron-donating or -withdrawing properties, respectively, of the groups on the phenyl ring at the side chain do not play a crucial role in the activity of the synthesized compounds.

Cytotoxic effects of the most active compounds were evaluated as well. The toxicity of all studied compounds increased in a dose-dependent manner, compounds **4e** and **4q** being the most toxic ones. Also, toxicity of **4q** increased with increasing incubation time. But toxicity of the other compounds decreased with increasing incubation time and their  $\text{IC}_{50}$  values were higher (Table IV).

In conclusion, a series of new 3(2*H*)-pyridazinone derivatives, **3a**, **3b**, and **4a–4r**, were synthesized in an effort to obtain new antimicrobial agents. All compounds were examined for their *in vitro* antimicrobial and antimycobacterial activities. The results of the preliminary activity tests of this class of compounds might lead to the development of better candidates with potent antimicrobial activities.

#### Acknowledgements

This study was supported by Gazi University Research Fund (project no. 02/2009-05).

Table IV. Cytotoxicity of compounds to the mouse fibroblast cell line NIH/3T3 after incubation for 24 h and 48 h, respectively.  $\text{IC}_{50}$  is the drug concentration required to inhibit the cell growth by 50%. The values represent means  $\pm$  standard deviations of triplicate determinations.

| Compound  | $\text{IC}_{50}$ [ $\mu\text{M}$ ] |                  |
|-----------|------------------------------------|------------------|
|           | 24 h                               | 48 h             |
| <b>4b</b> | 288.3 $\pm$ 24.6                   | 350.0 $\pm$ 17.3 |
| <b>4c</b> | 236.7 $\pm$ 32.5                   | 320 $\pm$ 10     |
| <b>4e</b> | 29.3 $\pm$ 4.04                    | 38 $\pm$ 3.46    |
| <b>4h</b> | 243.3 $\pm$ 11.5                   | 365 $\pm$ 21.8   |
| <b>4f</b> | 257.7 $\pm$ 6.8                    | 306.7 $\pm$ 115  |
| <b>4q</b> | 29.2 $\pm$ 1.44                    | 27.7 $\pm$ 0.6   |

- Aksoy D. Y. and Unal S. (2008), New antimicrobial agents for the treatment of Gram-positive bacterial infections. *Clin. Microbiol. Infect.* **14**, 411–420.
- Bansal R., Kumar D., Carron R., and Calle C. (2009), Synthesis and vasodilatory activity of some amide derivatives of 6-(4-carboxymethoxyphenyl)-4,5-dihydro-3(2*H*)-pyridazinone. *Eur. J. Med. Chem.* **44**, 4441–4447.
- Cherng S. C., Huang W. H., Shiau C. Y., Lee A. R., and Chou T. C. (2006), Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative. *Eur. J. Pharmacol.* **532**, 32–37.
- CLSI (formerly NCCLS) (2006), Performance Standards for Antimicrobial Disk Susceptibility Tests, Approved Standard, M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
- CLSI (formerly NCCLS) (2008a), Performance Standards for Antimicrobial Susceptibility Testing; 16th Informational Supplement. CLSI M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
- CLSI (formerly NCCLS) (2008b), Reference Method for Broth Dilution Antifungal Susceptibility Testing Yeast, Approved Standard, M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
- Demirayak S., Karaburun A. C., and Beis R. (2004), Some pyrrole substituted aryl pyridazinone and phthalazinone derivatives and their antihypertensive activities. *Eur. J. Med. Chem.* **39**, 1089–1095.
- Dogruer D. S., Sahin M. F., Kupeli E., and Yesilada E. (2003), Synthesis and analgesic and anti-inflammatory activity of new pyridazinones. *Turk. J. Chem.* **27**, 727–738.
- Dogruer D. S., Onkol T., Ozkan S., Ozgen S., and Sahin M. F. (2008), Synthesis and antimicrobial activity of some 3(2*H*)-pyridazinone and 1(2*H*)-phthalazinone derivatives. *Turk. J. Chem.* **32**, 469–479.
- Franzblau S. G. F., Witzig R. S., McLaughlin J. C., Torres P., Madico G., Hernandez A., Degnan M. T., Cook M. B., Quenzer V. K., Ferguson R. M., and Gilman R. H. (1998), Rapid, low-technology MIC determination with clinical *Mycobacterium tuberculosis* isolates by using the microplate Alamar Blue assay. *J. Clin. Microbiol.* **36**, 362–366.
- Gokce M., Utku S., and Kupeli E. (2009), Synthesis and analgesic and anti-inflammatory activities of 6-substituted-3(2*H*)-pyridazinone-2-acetyl-2-(*p*-substituted/nonsubstituted benzal)hydrazone derivatives. *Eur. J. Med. Chem.* **44**, 3760–3764.
- He Y., Wu B., Yang J., Robinson D., Risen L., Ranken R., Blyn L., Sheng S., and Swayze E. (2003), 2-Piperidin-4-yl-benzimidazoles with broad spectrum antibacterial activities. *Bioorg. Med. Chem. Lett.* **13**, 3253–3256.
- Keiser K., Johnson C. C., and Tipton D. A. (2000), Cytotoxicity of mineral trioxide aggregate using human periodontal ligament fibroblasts. *J. Endod.* **26**, 288–291.
- Liu X. H., Shi Y. X., Ma Y., He G. R., Dong W. L., Zhang C. Y., Wang B. L., Wang S. H., Li B. J., and Li Z. M. (2009), Synthesis of some *N,N'*-diacylhydrazine derivatives with radical-scavenging and antifungal activity. *Chem. Biol. Drug Res.* **73**, 320–327.
- Livermore D. G. H., Bethell R. C., and Cammack N. (1993), Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-*b*]pyridazines. *J. Med. Chem.* **36**, 3784–3794.
- Longo J. G., Verde I., and Castro M. E. (1993), Pyridazine derivatives. 11. Antihypertensive activity of 3-hydrazinocycloheptyl[1,2-*c*]pyridazine and its hydrazone derivatives. *J. Pharm. Sci.* **82**, 286–290.
- Malinka W., Redzicka A., and Lozach O. (2004), New derivatives of pyrrolo[3,4-*d*]pyridazinone and their anticancer effects. *Farmaco* **59**, 457–462.
- Mallikarjuna B. P., Sastry B. S., Suresh Kumar G. V., Rajendraprasad Y., Chandrashekar S. M., and Sathisha K. (2009), Synthesis of new 4-isopropylthiazole hydrazide analogs and some derived clubbed triazole, oxadiazole ring systems – A novel class of potential antibacterial, antifungal and antitubercular agents. *Eur. J. Med. Chem.* **44**, 4739–4746.
- Mossmann T. (1983), Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **65**, 55–63.
- Rubat C., Coudert P., Refouvet B., Tronche P., and Bastide P. (1990), Anticonvulsant activity of 3-oxo-5-substituted benzylidene-6-methyl-(4*H*)-2-pyridazinylacetamides and 2-pyridazinylacetylhydrazides. *Chem. Pharm. Bull.* **38**, 3009–3013.
- Siddiqui A. A., Mishra R., and Shaharyar M. (2010), Synthesis, characterization and antihypertensive activity of pyridazinone derivatives. *Eur. J. Med. Chem.* **45**, 2283–2290.
- Sönmez M., Berber I., and Akbaş E. (2006), Synthesis, antibacterial and antifungal activity of some new pyridazinone metal complexes. *Eur. J. Med. Chem.* **41**, 101–105.
- Sriram D., Yogeeswari P., and Devakaram R. V. (2006), Synthesis, *in vitro* and *in vivo* antimycobacterial activities of diclofenac acid hydrazones and amides. *Bioorg. Med. Chem.* **14**, 3113–3118.
- Sukuroglu M., Kupeli E., Banoglu E., Unlu S., Yesilada E., and Sahin M. F. (2006), Synthesis and analgesic activity of some 4,6-disubstituted-3(2*H*)-pyridazinone derivatives. *Arzneim.-Forsch./Drug Res.* **56**, 337–345.
- Sundriyal S., Sharma R. K., and Jain R. (2006), Current advances in antifungal targets and drug development. *Curr. Med. Chem.* **13**, 1321–1335.
- Suresh Kumar G. V., Rajendraprasad Y., Mallikarjuna B. P., Chandrashekar S. M., and Kistayya C. (2010), Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and 1,3,4-oxadiazoles as potential antimicrobial and antitubercular agents. *Eur. J. Med. Chem.* **45**, 2063–2074.